Intropin Side Effects
Generic name: dopamine
Medically reviewed by Drugs.com. Last updated on Mar 2, 2022.
Note: This document contains side effect information about dopamine. Some dosage forms listed on this page may not apply to the brand name Intropin.
Applies to dopamine: parenteral injection concentrate for iv infusion, parenteral injection for iv infusion.
A standardized concentration for this drug has been established through Standardize 4 Safety (S4S), a national patient safety initiative to reduce medication errors, especially during transitions of care. The drug is included in a standard concentration list which may apply to an IV or oral compounded liquid formulation. For additional information, see the ASHP website [Web].
Side effects include:
Dopamine (the active ingredient contained in Intropin) may cause cardiac conduction abnormalities (e.g., ventricular arrhythmia, atrial fibrillation, widened QRS complex, ectopic heartbeats), tachycardia, angina, palpitation, bradycardia, vasoconstriction, hypotension, hypertension, dyspnea, nausea, vomiting, headache, anxiety, azotemia, piloerection, and gangrene of the extremities.
For Healthcare Professionals
Applies to dopamine: intravenous solution.
Common (1% to 10%): Ectopic beats, tachycardia, anginal pain, palpitation, hypotension, vasoconstriction
Uncommon (0.1% to 1%): Aberrant ventricular conduction/ventricular arrhythmia, bradycardia, widened QRS complex, hypertension
Frequency not reported: Gangrene of the feet/extremities, peripheral cyanosis, fatal ventricular arrhythmias, atrial fibrillation, cardiac conduction abnormalities[Ref]
Gangrene of the feet occurred in patients with preexisting vascular disorders and/or at doses of at least 10 to 14 mcg/kg/min given for prolonged periods of time.
Ventricular arrhythmias occurred at very high doses.[Ref]
Common (1% to 10%): Nausea, vomiting[Ref]
Common (1% to 10%): Headache[Ref]
Common (1% to 10%): Dyspnea[Ref]
Very rare (less than 0.01%): Gangrene
Frequency not reported: Piloerection[Ref]
Frequency not reported: Necrosis, tissue sloughing, local ischemia and vasoconstriction[Ref]
Necrosis and tissue sloughing may be caused by extravasation of this drug.[Ref]
Frequency not reported: Anxiety[Ref]
Frequency not reported: Azotemia[Ref]
Frequency not reported: Mydriasis[Ref]
Frequency not reported: Hypovolemia[Ref]
Frequently asked questions
More about Intropin (dopamine)
Related treatment guides
1. "Product Information. Intropin (dopamine)." DuPont Pharmaceuticals (2002):
2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
3. Cerner Multum, Inc. "Australian Product Information." O 0
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.